--- title: "Piracetam: Dosing & Vendor Prices — BodyHackGuide" description: "Piracetam: dosing protocols, mechanism & side effects, 23 PubMed studies. Compare verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Piracetam" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Piracetam", "description": "Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term \"nootropic\" (from the Greek nous for mind and tropos for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other \"nootropics\" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including Noopept, Modafinil, Sulbutiamine, Bromantane, Selank, Semax, Lion's Mane, Uridine Monophosphate, NAD+, Methylene Blue, L-Theanine, and L-Tyrosine; and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice.", "lastReviewed": "2026-05-04T11:34:56.484+00:00", "url": "https://www.bodyhackguide.co/compound/piracetam", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Piracetam", "alternateName": [ "Nootropil", "Lucetam", "Pirabene", "UCB-6215", "2-oxo-1-pyrrolidineacetamide", "2-oxo-1-pyrrolidinylacetamide" ], "description": "Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term \"nootropic\" (from the Greek nous for mind and tropos for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other \"nootropics\" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including Noopept, Modafinil, Sulbutiamine, Bromantane, Selank, Semax, Lion's Mane, Uridine Monophosphate, NAD+, Methylene Blue, L-Theanine, and L-Tyrosine; and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice.", "activeIngredient": "Piracetam", "mechanismOfAction": "Piracetam's mechanism of action is the subject of 50+ years of research that has identified several pharmacologic effects without converging on a single primary mechanism. The compound is a cyclic derivative of GABA but has minimal direct GABAergic activity — it does not bind meaningfully to GABA-A or GABA-B receptors and does not affect GABA reuptake or metabolism. This disconnect between structural heritage and functional pharmacology was part of what attracted Giurgea's attention when characterizing the compound in the 1960s. The best-characterized molecular effect of piracetam is modulation of AMPA-type glutamate receptors. Piracetam binds to AMPA receptors at an allosteric site and produces positive modulation of AMPA-mediated glutamatergic neurotransmission, particularly under conditions of increased synaptic activity. This AMPAkine effect is shared with other racetams (aniracetam, oxiracetam) and with the broader AMPAkine drug class including newer selective AMPA positive modulators. The functional consequence is enhanced long-term potentiation (LTP) at glutamatergic synapses, the cellular basis for associative learning and memory formation. Piracetam's effects on membrane fluidity are a distinct and important mechanistic feature. Studies using electron paramagnetic resonance and fluorescence polarization techniques have shown that piracetam restores age-related reductions in membrane fluidity in neuronal membranes, enhances the ability of membrane-embedded receptors to undergo conformational changes required for function, and normalizes ion channel dynamics in aged or pathologic membranes. This mechanism — membrane normalization — is unusual among CNS drugs and may explain some of piracetam's cognitive effects in aging populations where membrane alterations contribute to cognitive decline. Effects on cerebral blood flow and oxygen utilization are well-documented. Piracetam increases cerebral blood flow in oxygen-deprived or hypoperfused brain regions without significantly altering flow in normally perfused tissue, and it improves cerebral oxygen and glucose utilization under conditions of metabolic stress. This regional selectivity — preferential effects on compromised tissue — aligns with piracetam's clinical use in cerebrovascular cognitive impairment and post-stroke cognitive dysfunction. Effects on cholinergic transmission are modest but contribute to the cognitive enhancement effect. Piracetam does not directly affect acetylcholine synthesis or breakdown but may improve cholinergic receptor sensitivity and facilitate cholinergic transmission in cortex and hippocampus. This effect is the mechanistic basis for the \"piracetam headache\" that occurs when cholinergic demand exceeds choline precursor supply — users commonly co-supplement choline sources (alpha-GPC, citicoline, choline bitartrate) to prevent headache. Effects on platelet function include antiplatelet activity comparable to aspirin at therapeutic doses, which contributed to historical interest in piracetam for stroke prevention and which requires attention in users with bleeding risks or on anticoagulants. Effects on erythrocyte deformability improve red blood cell passage through small blood vessels, which may contribute to the improved microcirculation observed in piracetam-treated patients. Effects on vestibular function underlie the European approval of piracetam for certain vertigo conditions. The pharmacokinetics of piracetam are relatively simple and favorable. Oral bioavailability is nearly 100%, reflecting good intestinal absorption and no significant first-pass hepatic metabolism. Peak plasma concentrations occur 30-60 minutes after oral dosing in fasting conditions (slightly longer with food). The terminal elimination half-life is approximately 5 hours, which produces the conventional three-times-daily dosing regimen used in most clinical protocols to maintain steady-state plasma levels. Piracetam is minimally metabolized and excreted almost entirely unchanged in the urine, which means renal impairment significantly affects clearance and requires dose reduction in advanced kidney disease. Hepatic impairment does not affect piracetam pharmacokinetics. The compound does not significantly inhibit or induce cytochrome P450 enzymes, which makes drug-drug interactions minimal — this is one of piracetam's distinguishing features and contributes to its favorable tolerability in polypharmacy contexts. Piracetam crosses the blood-brain barrier efficiently and achieves CNS concentrations comparable to plasma concentrations within 30-60 minutes of dosing. Effects on the cognitive enhancement side are not typically noticeable from a single dose — most users require 1-2 weeks of consistent dosing to reach maximal subjective and objective benefit, which aligns with piracetam's mechanism of gradual modulation of receptor function, membrane properties, and neural function rather than acute neurotransmitter effects.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is piracetam and what is it used for?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam is the prototypical nootropic drug, synthesized by Corneliu Giurgea at UCB in 1964 and the compound that led Giurgea to coin the term 'nootropic' in 1972. It is approved in dozens of countries outside the US for cortical myoclonus, age-related cognitive decline, dyslexia in children, alcoholic dementia, vertigo, and other indications. It is not FDA-approved in the US but widely available through online retailers and compounding pharmacies. Used as a general cognitive enhancer with favorable safety profile and 50+ years of clinical use." } }, { "@type": "Question", "name": "How does piracetam work?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam's mechanism is incompletely understood but involves positive modulation of AMPA-type glutamate receptors (AMPAkine effect), enhancement of neuronal membrane fluidity, improvement of cerebral blood flow particularly in hypoperfused regions, modest enhancement of cholinergic transmission, and antiplatelet activity. It does not directly activate any single neurotransmitter system. The lack of dramatic acute effects reflects its mechanism of gradual modulation of neural function rather than acute neurotransmitter release." } }, { "@type": "Question", "name": "What is the best piracetam dose?", "acceptedAnswer": { "@type": "Answer", "text": "The standard clinical dose is 1600 mg three times daily (4.8 g total daily), which has been used in most European cognitive decline trials. Range of 2.4-9.6 g daily covers most use cases; higher doses (up to 24 g daily) are used for cortical myoclonus. Most users require 1-2 weeks of consistent dosing before noticing effects. Loading dose protocols (9.6 g daily for 3-7 days, then maintenance) may accelerate onset. Renal impairment requires dose reduction." } }, { "@type": "Question", "name": "Why do I need to take choline with piracetam?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam modulates cholinergic transmission and can deplete the brain's choline pool at therapeutic doses, producing headache in 5-15% of users. Choline supplementation prevents this headache in most cases. Alpha-GPC 300-600 mg daily, citicoline 250-500 mg daily, or choline bitartrate 500-1000 mg daily are the standard options. Alpha-GPC and citicoline are more efficient for CNS delivery; choline bitartrate is less expensive. Choline co-supplementation is standard practice based on decades of nootropic community experience." } }, { "@type": "Question", "name": "Is piracetam legal in the United States?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam is not FDA-approved for any medical indication and is not a legal dietary supplement under the FDA's interpretation of DSHEA. The FDA has issued warning letters to companies marketing piracetam-containing supplements. However, piracetam remains widely available in the US through online retailers, compounding pharmacies, and research chemical vendors. Possession and personal use are not criminally enforced, but interstate sale of piracetam as a dietary supplement is technically a regulatory violation. Users should be aware of this regulatory situation." } }, { "@type": "Question", "name": "How does piracetam compare to noopept?", "acceptedAnswer": { "@type": "Answer", "text": "Both compounds are cognitive enhancers with racetam-class origins and are commonly stacked together. Noopept is approximately 1000x more potent by weight (doses are measured in mg vs. piracetam's grams), has different pharmacokinetics (shorter half-life, faster onset), and is proposed to work partly through BDNF/NGF upregulation. Piracetam has longer clinical track record, broader evidence base, and wider range of approved clinical indications. Many users find the combination more effective than either alone — piracetam for broad cognitive support, noopept for more acute memory and processing effects." } }, { "@type": "Question", "name": "Will piracetam make me smarter?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam produces modest cognitive effects, particularly in users with baseline impairment (age-related cognitive decline, cerebrovascular disease, cognitive effects of alcoholism). In healthy young adults without cognitive impairment, effects are subtle and may not be subjectively dramatic. Piracetam does not substantially increase intelligence in any meaningful long-term sense — it modulates specific aspects of cognitive function (working memory, sustained attention, processing speed) while the compound is present. Users expecting dramatic cognitive transformation will generally be disappointed." } }, { "@type": "Question", "name": "Can I take piracetam with other nootropics like modafinil, lion's mane, or noopept?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, piracetam stacks well with most other nootropics and has minimal drug interactions. Common combinations include piracetam + Noopept + alpha-GPC (the classic racetam + choline + potentiator stack), piracetam + Modafinil for acute + sustained cognitive support, piracetam + Lion's Mane for pharmacologic + neurotrophic effects, piracetam + Sulbutiamine for dopaminergic overlay. Always include a choline source when using piracetam. Anticoagulants/antiplatelets are the main category warranting caution due to piracetam's own antiplatelet activity." } }, { "@type": "Question", "name": "Is piracetam safe for long-term use?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, within reasonable dose ranges and appropriate monitoring. The clinical literature from European cognitive decline practice documents safe use over years in patients with minimal adverse effects. Piracetam has an exceptional safety record — no documented organ toxicity, no addiction, no meaningful withdrawal. Key monitoring concerns for long-term use: renal function (dose adjustment for impairment), platelet function (especially with anticoagulants or surgery), and psychiatric status (rare mood or activation effects). Periodic cycling (6-8 weeks on, 1-2 weeks off) is empirical rather than mechanistically necessary but reveals baseline and prevents subtle psychological dependence." } }, { "@type": "Question", "name": "What are the most important piracetam side effects to watch for?", "acceptedAnswer": { "@type": "Answer", "text": "Common: headache (prevented by choline co-supplementation), mild GI upset, occasional nervousness, rare sleep disturbance (avoid late-day dosing). Uncommon but important: bleeding effects from antiplatelet activity (particularly with anticoagulants, before surgery, or in bleeding disorders); psychiatric activation or mood changes in susceptible users (particularly bipolar disorder). Rare: allergic reactions, paradoxical worsening of cognitive function in Huntington's disease. Discontinue and seek medical evaluation for any unexplained rash, significant bleeding, severe anxiety or mood changes, or persistent adverse effects. Most users tolerate piracetam very well with only the headache concern requiring attention." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Piracetam", "description": "Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term \"nootropic\" (from the Greek nous for mind and tropos for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other \"nootropics\" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including Noopept, Modafinil, Sulbutiamine, Bromantane, Selank, Semax, Lion's Mane, Uridine Monophosphate, NAD+, Methylene Blue, L-Theanine, and L-Tyrosine; and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice.", "lastReviewed": "2026-05-04T11:34:56.484+00:00", "url": "https://www.bodyhackguide.co/compound/piracetam", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Piracetam", "alternateName": [ "Nootropil", "Lucetam", "Pirabene", "UCB-6215", "2-oxo-1-pyrrolidineacetamide", "2-oxo-1-pyrrolidinylacetamide" ], "description": "Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term \"nootropic\" (from the Greek nous for mind and tropos for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other \"nootropics\" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including Noopept, Modafinil, Sulbutiamine, Bromantane, Selank, Semax, Lion's Mane, Uridine Monophosphate, NAD+, Methylene Blue, L-Theanine, and L-Tyrosine; and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice.", "activeIngredient": "Piracetam", "mechanismOfAction": "Piracetam's mechanism of action is the subject of 50+ years of research that has identified several pharmacologic effects without converging on a single primary mechanism. The compound is a cyclic derivative of GABA but has minimal direct GABAergic activity — it does not bind meaningfully to GABA-A or GABA-B receptors and does not affect GABA reuptake or metabolism. This disconnect between structural heritage and functional pharmacology was part of what attracted Giurgea's attention when characterizing the compound in the 1960s. The best-characterized molecular effect of piracetam is modulation of AMPA-type glutamate receptors. Piracetam binds to AMPA receptors at an allosteric site and produces positive modulation of AMPA-mediated glutamatergic neurotransmission, particularly under conditions of increased synaptic activity. This AMPAkine effect is shared with other racetams (aniracetam, oxiracetam) and with the broader AMPAkine drug class including newer selective AMPA positive modulators. The functional consequence is enhanced long-term potentiation (LTP) at glutamatergic synapses, the cellular basis for associative learning and memory formation. Piracetam's effects on membrane fluidity are a distinct and important mechanistic feature. Studies using electron paramagnetic resonance and fluorescence polarization techniques have shown that piracetam restores age-related reductions in membrane fluidity in neuronal membranes, enhances the ability of membrane-embedded receptors to undergo conformational changes required for function, and normalizes ion channel dynamics in aged or pathologic membranes. This mechanism — membrane normalization — is unusual among CNS drugs and may explain some of piracetam's cognitive effects in aging populations where membrane alterations contribute to cognitive decline. Effects on cerebral blood flow and oxygen utilization are well-documented. Piracetam increases cerebral blood flow in oxygen-deprived or hypoperfused brain regions without significantly altering flow in normally perfused tissue, and it improves cerebral oxygen and glucose utilization under conditions of metabolic stress. This regional selectivity — preferential effects on compromised tissue — aligns with piracetam's clinical use in cerebrovascular cognitive impairment and post-stroke cognitive dysfunction. Effects on cholinergic transmission are modest but contribute to the cognitive enhancement effect. Piracetam does not directly affect acetylcholine synthesis or breakdown but may improve cholinergic receptor sensitivity and facilitate cholinergic transmission in cortex and hippocampus. This effect is the mechanistic basis for the \"piracetam headache\" that occurs when cholinergic demand exceeds choline precursor supply — users commonly co-supplement choline sources (alpha-GPC, citicoline, choline bitartrate) to prevent headache. Effects on platelet function include antiplatelet activity comparable to aspirin at therapeutic doses, which contributed to historical interest in piracetam for stroke prevention and which requires attention in users with bleeding risks or on anticoagulants. Effects on erythrocyte deformability improve red blood cell passage through small blood vessels, which may contribute to the improved microcirculation observed in piracetam-treated patients. Effects on vestibular function underlie the European approval of piracetam for certain vertigo conditions. The pharmacokinetics of piracetam are relatively simple and favorable. Oral bioavailability is nearly 100%, reflecting good intestinal absorption and no significant first-pass hepatic metabolism. Peak plasma concentrations occur 30-60 minutes after oral dosing in fasting conditions (slightly longer with food). The terminal elimination half-life is approximately 5 hours, which produces the conventional three-times-daily dosing regimen used in most clinical protocols to maintain steady-state plasma levels. Piracetam is minimally metabolized and excreted almost entirely unchanged in the urine, which means renal impairment significantly affects clearance and requires dose reduction in advanced kidney disease. Hepatic impairment does not affect piracetam pharmacokinetics. The compound does not significantly inhibit or induce cytochrome P450 enzymes, which makes drug-drug interactions minimal — this is one of piracetam's distinguishing features and contributes to its favorable tolerability in polypharmacy contexts. Piracetam crosses the blood-brain barrier efficiently and achieves CNS concentrations comparable to plasma concentrations within 30-60 minutes of dosing. Effects on the cognitive enhancement side are not typically noticeable from a single dose — most users require 1-2 weeks of consistent dosing to reach maximal subjective and objective benefit, which aligns with piracetam's mechanism of gradual modulation of receptor function, membrane properties, and neural function rather than acute neurotransmitter effects.", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is piracetam and what is it used for?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam is the prototypical nootropic drug, synthesized by Corneliu Giurgea at UCB in 1964 and the compound that led Giurgea to coin the term 'nootropic' in 1972. It is approved in dozens of countries outside the US for cortical myoclonus, age-related cognitive decline, dyslexia in children, alcoholic dementia, vertigo, and other indications. It is not FDA-approved in the US but widely available through online retailers and compounding pharmacies. Used as a general cognitive enhancer with favorable safety profile and 50+ years of clinical use." } }, { "@type": "Question", "name": "How does piracetam work?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam's mechanism is incompletely understood but involves positive modulation of AMPA-type glutamate receptors (AMPAkine effect), enhancement of neuronal membrane fluidity, improvement of cerebral blood flow particularly in hypoperfused regions, modest enhancement of cholinergic transmission, and antiplatelet activity. It does not directly activate any single neurotransmitter system. The lack of dramatic acute effects reflects its mechanism of gradual modulation of neural function rather than acute neurotransmitter release." } }, { "@type": "Question", "name": "What is the best piracetam dose?", "acceptedAnswer": { "@type": "Answer", "text": "The standard clinical dose is 1600 mg three times daily (4.8 g total daily), which has been used in most European cognitive decline trials. Range of 2.4-9.6 g daily covers most use cases; higher doses (up to 24 g daily) are used for cortical myoclonus. Most users require 1-2 weeks of consistent dosing before noticing effects. Loading dose protocols (9.6 g daily for 3-7 days, then maintenance) may accelerate onset. Renal impairment requires dose reduction." } }, { "@type": "Question", "name": "Why do I need to take choline with piracetam?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam modulates cholinergic transmission and can deplete the brain's choline pool at therapeutic doses, producing headache in 5-15% of users. Choline supplementation prevents this headache in most cases. Alpha-GPC 300-600 mg daily, citicoline 250-500 mg daily, or choline bitartrate 500-1000 mg daily are the standard options. Alpha-GPC and citicoline are more efficient for CNS delivery; choline bitartrate is less expensive. Choline co-supplementation is standard practice based on decades of nootropic community experience." } }, { "@type": "Question", "name": "Is piracetam legal in the United States?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam is not FDA-approved for any medical indication and is not a legal dietary supplement under the FDA's interpretation of DSHEA. The FDA has issued warning letters to companies marketing piracetam-containing supplements. However, piracetam remains widely available in the US through online retailers, compounding pharmacies, and research chemical vendors. Possession and personal use are not criminally enforced, but interstate sale of piracetam as a dietary supplement is technically a regulatory violation. Users should be aware of this regulatory situation." } }, { "@type": "Question", "name": "How does piracetam compare to noopept?", "acceptedAnswer": { "@type": "Answer", "text": "Both compounds are cognitive enhancers with racetam-class origins and are commonly stacked together. Noopept is approximately 1000x more potent by weight (doses are measured in mg vs. piracetam's grams), has different pharmacokinetics (shorter half-life, faster onset), and is proposed to work partly through BDNF/NGF upregulation. Piracetam has longer clinical track record, broader evidence base, and wider range of approved clinical indications. Many users find the combination more effective than either alone — piracetam for broad cognitive support, noopept for more acute memory and processing effects." } }, { "@type": "Question", "name": "Will piracetam make me smarter?", "acceptedAnswer": { "@type": "Answer", "text": "Piracetam produces modest cognitive effects, particularly in users with baseline impairment (age-related cognitive decline, cerebrovascular disease, cognitive effects of alcoholism). In healthy young adults without cognitive impairment, effects are subtle and may not be subjectively dramatic. Piracetam does not substantially increase intelligence in any meaningful long-term sense — it modulates specific aspects of cognitive function (working memory, sustained attention, processing speed) while the compound is present. Users expecting dramatic cognitive transformation will generally be disappointed." } }, { "@type": "Question", "name": "Can I take piracetam with other nootropics like modafinil, lion's mane, or noopept?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, piracetam stacks well with most other nootropics and has minimal drug interactions. Common combinations include piracetam + Noopept + alpha-GPC (the classic racetam + choline + potentiator stack), piracetam + Modafinil for acute + sustained cognitive support, piracetam + Lion's Mane for pharmacologic + neurotrophic effects, piracetam + Sulbutiamine for dopaminergic overlay. Always include a choline source when using piracetam. Anticoagulants/antiplatelets are the main category warranting caution due to piracetam's own antiplatelet activity." } }, { "@type": "Question", "name": "Is piracetam safe for long-term use?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, within reasonable dose ranges and appropriate monitoring. The clinical literature from European cognitive decline practice documents safe use over years in patients with minimal adverse effects. Piracetam has an exceptional safety record — no documented organ toxicity, no addiction, no meaningful withdrawal. Key monitoring concerns for long-term use: renal function (dose adjustment for impairment), platelet function (especially with anticoagulants or surgery), and psychiatric status (rare mood or activation effects). Periodic cycling (6-8 weeks on, 1-2 weeks off) is empirical rather than mechanistically necessary but reveals baseline and prevents subtle psychological dependence." } }, { "@type": "Question", "name": "What are the most important piracetam side effects to watch for?", "acceptedAnswer": { "@type": "Answer", "text": "Common: headache (prevented by choline co-supplementation), mild GI upset, occasional nervousness, rare sleep disturbance (avoid late-day dosing). Uncommon but important: bleeding effects from antiplatelet activity (particularly with anticoagulants, before surgery, or in bleeding disorders); psychiatric activation or mood changes in susceptible users (particularly bipolar disorder). Rare: allergic reactions, paradoxical worsening of cognitive function in Huntington's disease. Discontinue and seek medical evaluation for any unexplained rash, significant bleeding, severe anxiety or mood changes, or persistent adverse effects. Most users tolerate piracetam very well with only the headache concern requiring attention." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fpiracetam) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Piracetam [Where to buy Piracetam](/buy/piracetam) [Piracetam coupon codes](/coupons/piracetam) [Piracetam protocol](/protocol/piracetam) [Alternatives to Piracetam](/alternatives-to/piracetam) [Piracetam side effects](/side-effects/piracetam) 1. [Home](/) 3. [Compounds](/compare) 5. Piracetam # Piracetam Nootropics Preclinical Download PDF Also known as: Nootropil, Lucetam, Pirabene, UCB-6215, 2-oxo-1-pyrrolidineacetamide, 2-oxo-1-pyrrolidinylacetamide Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. [23 PubMed Studies](https://pubmed.ncbi.nlm.nih.gov/?term=piracetam%20cognitive%20enhancement%20nootropic) Last reviewed: May 4, 2026 [ 23 PubMed Studies ](https://pubmed.ncbi.nlm.nih.gov/?term=piracetam%20cognitive%20enhancement%20nootropic)[ Nootropics Category ](/wiki#cat-nootropics) Preclinical Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated ## Overview ### At A Glance Mechanism Piracetam's mechanism of action is the subject of 50+ years of research that has identified several pharmacologic effects without converging on a single primary mechanism. The compound is a cyclic derivative of GABA but has minimal direct GABAergic activity — it does not bind mea… ### Overview Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term "nootropic" (from the Greek _nous_ for mind and _tropos_ for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other "nootropics" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including [Noopept](/compound/noopept), [Modafinil](/compound/modafinil), [Sulbutiamine](/compound/sulbutiamine), [Bromantane](/compound/bromantane), [Selank](/compound/selank), [Semax](/compound/semax), [Lion's Mane](/compound/lions-mane), [Uridine Monophosphate](/compound/uridine-monophosphate), [NAD+](/compound/nad), [Methylene Blue](/compound/methylene-blue), [L-Theanine](/compound/l-theanine), and [L-Tyrosine](/compound/l-tyrosine); and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice. ## Chemical Information IUPAC Name Not yet available CAS Number Not yet available Molecular Formula Not yet available Molecular Mass Not yet available Chemical data is being compiled for this compound. ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Piracetam has a favorable contraindication profile reflecting its excellent safety record over 50+ years of clinical use. Absolute contraindications are few: known hypersensitivity or allergy to piracetam or any component of the preparation; severe renal impairment (end-stage renal disease, particularly without dialysis); and Huntington's disease, where piracetam can paradoxically worsen symptoms. Pregnancy is a relative contraindication — piracetam crosses the placenta and no adequate controlled studies have been conducted in pregnant women. While no specific teratogenic signal has emerged from clinical use, the absence of pregnancy-specific evidence makes routine use during pregnancy inappropriate. If piracetam is used during pregnancy for compelling indications (cortical myoclonus, severe cognitive impairment affecting maternal function), the balance of risks and benefits should be specifically evaluated with the prescribing physician. Breastfeeding is a relative contraindication for similar reasons — piracetam is excreted in breast milk at clinically relevant concentrations, and effects on nursing infants are not well characterized. Most clinicians recommend avoiding piracetam while breastfeeding. Renal impairment of any severity requires dose adjustment. Mild impairment (CrCl 50-79 mL/min): standard dose. Moderate impairment (30-49 mL/min): 50% dose reduction. Severe impairment (<30 mL/min): 75% dose reduction or avoid use. End-stage renal disease: avoid or dose after hemodialysis sessions. Bleeding disorders are a relative contraindication or warrant specific caution. Piracetam's antiplatelet activity comparable to low-dose aspirin at therapeutic doses theoretically increases bleeding risk in users with hemophilia, von Willebrand disease, thrombocytopenia, or other bleeding disorders. Users with these conditions should consult hematology before starting piracetam. Concurrent anticoagulation or antiplatelet therapy is a relative contraindication depending on the specific combination and clinical context. Users on warfarin, direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban), aspirin, clopidogrel, ticagrelor, or other antiplatelet/anticoagulant drugs should coordinate piracetam use with their prescribing physician, monitor for increased bleeding, and discontinue piracetam 1-2 weeks before elective surgical procedures. Recent intracerebral hemorrhage or hemorrhagic stroke is a stronger contraindication — the antiplatelet effect could theoretically worsen bleeding outcomes. Bipolar disorder and other mood disorders are relative contraindications. Case reports exist of piracetam precipitating hypomania or mania in susceptible individuals. Users with bipolar disorder should use piracetam only under psychiatric supervision with mood monitoring. Psychosis and schizophrenia are relative contraindications — while piracetam has been used in some schizophrenia trials, the potential for rare psychiatric activation warrants psychiatric oversight. Severe anxiety disorders may be worsened by piracetam's subtle activation, though effects vary individually. Age considerations: pediatric use is approved in some European countries for specific indications (dyslexia, cortical myoclonus) and is considered safe at appropriate doses. Elderly patients may benefit most from piracetam's cognitive effects but require dose adjustment for age-related renal impairment and closer monitoring. No specific contraindication for age. Surgical considerations: elective surgery should be preceded by 1-2 weeks of piracetam discontinuation to allow platelet function to normalize. Emergency surgery while on piracetam is usually not problematic but should be communicated to the anesthesia team for consideration of platelet support if significant bleeding occurs. Drug interactions of concern are few. The main interactions are: anticoagulants and antiplatelets (additive bleeding risk); thyroid hormone replacement (piracetam may slightly improve effects, usually clinically minor); amphetamine-class stimulants (anecdotal reports of anxiety or synergy). Piracetam does not significantly affect cytochrome P450 enzymes and is considered one of the most drug-interaction-friendly compounds in the pharmacologic space. Specific combinations worth noting: piracetam + alcohol — piracetam may increase alcohol's subjective effects, and combination is often reported as particularly intoxicating, warranting caution; piracetam + other racetams — generally safe but produces diminishing marginal returns; piracetam + high-dose caffeine — increases anxiety in sensitive users. Absence of medical evaluation is the final consideration. While piracetam's safety profile supports non-medical use in appropriate contexts, users with significant medical conditions (cardiovascular disease, kidney disease, psychiatric disorders, bleeding disorders) should involve their physicians in the decision to use piracetam. Self-experimentation with a compound that is not FDA-approved and operates in a regulatory grey area requires the user to take responsibility for their own medical evaluation and risk assessment — a responsibility best discharged with physician partnership rather than entirely independently. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. [Sign in for alerts ](/auth) No listings found for Piracetam. Get Piracetam Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Piracetam. [Sign in](/auth) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa)[ ### Kavain Nootropics Preclinical for isolated kavain (in-vitro and animal mechanistic data). Human randomized controlled trials exist for the parent standardized kava extract, of which kavain is the principal kavalactone; the single molecule itself has not been trialed alone. Kavain (kawain) is the principal kavalactone in kava (Piper methysticum) and the main compound behind kava's calming, anxiolytic effect. t½ Not firmly established for isolated kavain in humans. Kavalactones are lipophilic and rapidly absorbed, with subjective effects generally lasting a few hours. Limited pharmacokinetic data preclude a precise elimination half-life. 50000-250000 Preclinical View Profile ](/compound/kavain)[ ### KW-6356 Nootropics Phase 2b (program discontinued) KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Preclinical View Profile ](/compound/kw-6356)[ ### L-Theanine Nootropics FDA Approved L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack. t½ 1-3 hours (plasma); central CNS effect 3-5 hours 1226 studies View Profile ](/compound/l-theanine) ### Side-by-Side Comparisons [All Comparisons](/compare) [Piracetam vs Noopept](/compare/noopept-vs-piracetam "Noopept vs Piracetam")[Piracetam vs Phenylpiracetam](/compare/phenylpiracetam-vs-piracetam "Phenylpiracetam vs Piracetam") [ View Full Dosage Guide → Protocols, calculator & safety for Piracetam ](/guides/dosage/piracetam) ### Related Articles [All Posts](/blog) [ #### Cognitive Enhancers by Mechanism and Safety: A Reference Guide A mechanism-first reference that groups cognitive enhancers into seven pharmacological classes and compares each on how it works and its main safety consideration, with a master table and honest evidence labels. Not a ranking, and not medical advice. 7/1/2026 ](/blog/cognitive-enhancers-by-mechanism-and-safety) ### Research Score 17 23 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings Research Credibility 23 PubMed studies ### Quick Facts Trial Phase Preclinical [Full Dosage Guide](/guides/dosage/piracetam)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is piracetam and what is it used for? Piracetam is the prototypical nootropic drug, synthesized by Corneliu Giurgea at UCB in 1964 and the compound that led Giurgea to coin the term 'nootropic' in 1972. It is approved in dozens of countries outside the US for cortical myoclonus, age-related cognitive decline, dyslexia in children, alcoholic dementia, vertigo, and other indications. It is not FDA-approved in the US but widely available through online retailers and compounding pharmacies. Used as a general cognitive enhancer with favorable safety profile and 50+ years of clinical use. How does piracetam work? Piracetam's mechanism is incompletely understood but involves positive modulation of AMPA-type glutamate receptors (AMPAkine effect), enhancement of neuronal membrane fluidity, improvement of cerebral blood flow particularly in hypoperfused regions, modest enhancement of cholinergic transmission, and antiplatelet activity. It does not directly activate any single neurotransmitter system. The lack of dramatic acute effects reflects its mechanism of gradual modulation of neural function rather than acute neurotransmitter release. What is the best piracetam dose? The standard clinical dose is 1600 mg three times daily (4.8 g total daily), which has been used in most European cognitive decline trials. Range of 2.4-9.6 g daily covers most use cases; higher doses (up to 24 g daily) are used for cortical myoclonus. Most users require 1-2 weeks of consistent dosing before noticing effects. Loading dose protocols (9.6 g daily for 3-7 days, then maintenance) may accelerate onset. Renal impairment requires dose reduction. Why do I need to take choline with piracetam? Piracetam modulates cholinergic transmission and can deplete the brain's choline pool at therapeutic doses, producing headache in 5-15% of users. Choline supplementation prevents this headache in most cases. Alpha-GPC 300-600 mg daily, citicoline 250-500 mg daily, or choline bitartrate 500-1000 mg daily are the standard options. Alpha-GPC and citicoline are more efficient for CNS delivery; choline bitartrate is less expensive. Choline co-supplementation is standard practice based on decades of nootropic community experience. Is piracetam legal in the United States? Piracetam is not FDA-approved for any medical indication and is not a legal dietary supplement under the FDA's interpretation of DSHEA. The FDA has issued warning letters to companies marketing piracetam-containing supplements. However, piracetam remains widely available in the US through online retailers, compounding pharmacies, and research chemical vendors. Possession and personal use are not criminally enforced, but interstate sale of piracetam as a dietary supplement is technically a regulatory violation. Users should be aware of this regulatory situation. How does piracetam compare to noopept? Both compounds are cognitive enhancers with racetam-class origins and are commonly stacked together. [Noopept](/compound/noopept) is approximately 1000x more potent by weight (doses are measured in mg vs. piracetam's grams), has different pharmacokinetics (shorter half-life, faster onset), and is proposed to work partly through BDNF/NGF upregulation. Piracetam has longer clinical track record, broader evidence base, and wider range of approved clinical indications. Many users find the combination more effective than either alone — piracetam for broad cognitive support, noopept for more acute memory and processing effects. Will piracetam make me smarter? Piracetam produces modest cognitive effects, particularly in users with baseline impairment (age-related cognitive decline, cerebrovascular disease, cognitive effects of alcoholism). In healthy young adults without cognitive impairment, effects are subtle and may not be subjectively dramatic. Piracetam does not substantially increase intelligence in any meaningful long-term sense — it modulates specific aspects of cognitive function (working memory, sustained attention, processing speed) while the compound is present. Users expecting dramatic cognitive transformation will generally be disappointed. Can I take piracetam with other nootropics like modafinil, lion's mane, or noopept? Yes, piracetam stacks well with most other nootropics and has minimal drug interactions. Common combinations include piracetam + [Noopept](/compound/noopept) + alpha-GPC (the classic racetam + choline + potentiator stack), piracetam + [Modafinil](/compound/modafinil) for acute + sustained cognitive support, piracetam + [Lion's Mane](/compound/lions-mane) for pharmacologic + neurotrophic effects, piracetam + [Sulbutiamine](/compound/sulbutiamine) for dopaminergic overlay. Always include a choline source when using piracetam. Anticoagulants/antiplatelets are the main category warranting caution due to piracetam's own antiplatelet activity. Is piracetam safe for long-term use? Yes, within reasonable dose ranges and appropriate monitoring. The clinical literature from European cognitive decline practice documents safe use over years in patients with minimal adverse effects. Piracetam has an exceptional safety record — no documented organ toxicity, no addiction, no meaningful withdrawal. Key monitoring concerns for long-term use: renal function (dose adjustment for impairment), platelet function (especially with anticoagulants or surgery), and psychiatric status (rare mood or activation effects). Periodic cycling (6-8 weeks on, 1-2 weeks off) is empirical rather than mechanistically necessary but reveals baseline and prevents subtle psychological dependence. What are the most important piracetam side effects to watch for? Common: headache (prevented by choline co-supplementation), mild GI upset, occasional nervousness, rare sleep disturbance (avoid late-day dosing). Uncommon but important: bleeding effects from antiplatelet activity (particularly with anticoagulants, before surgery, or in bleeding disorders); psychiatric activation or mood changes in susceptible users (particularly bipolar disorder). Rare: allergic reactions, paradoxical worsening of cognitive function in Huntington's disease. Discontinue and seek medical evaluation for any unexplained rash, significant bleeding, severe anxiety or mood changes, or persistent adverse effects. Most users tolerate piracetam very well with only the headache concern requiring attention. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa)[ ### Kavain Nootropics Preclinical for isolated kavain (in-vitro and animal mechanistic data). Human randomized controlled trials exist for the parent standardized kava extract, of which kavain is the principal kavalactone; the single molecule itself has not been trialed alone. Kavain (kawain) is the principal kavalactone in kava (Piper methysticum) and the main compound behind kava's calming, anxiolytic effect. t½ Not firmly established for isolated kavain in humans. Kavalactones are lipophilic and rapidly absorbed, with subjective effects generally lasting a few hours. Limited pharmacokinetic data preclude a precise elimination half-life. 50000-250000 Preclinical View Profile ](/compound/kavain)[ ### KW-6356 Nootropics Phase 2b (program discontinued) KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa. Preclinical View Profile ](/compound/kw-6356)[ ### L-Theanine Nootropics FDA Approved L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack. t½ 1-3 hours (plasma); central CNS effect 3-5 hours 1226 studies View Profile ](/compound/l-theanine) ## Side-by-Side Comparisons [All Comparisons](/compare) Compare Piracetam head-to-head: mechanism, half-life, dosing, safety, and live pricing. [Piracetam vs Noopept](/compare/noopept-vs-piracetam "Noopept vs Piracetam")[Piracetam vs Phenylpiracetam](/compare/phenylpiracetam-vs-piracetam "Phenylpiracetam vs Piracetam") Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-piracetam) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋